Daytime sleepiness in Japanese patients with multiple system atrophy: prevalence and determinants by Takayoshi Shimohata et al.
Shimohata et al. BMC Neurology 2012, 12:130
http://www.biomedcentral.com/1471-2377/12/130RESEARCH ARTICLE Open AccessDaytime sleepiness in Japanese patients with
multiple system atrophy: prevalence and
determinants
Takayoshi Shimohata1*, Hideaki Nakayama2, Masahiko Tomita3, Tetsutaro Ozawa1 and Masatoyo Nishizawa1Abstract
Background: The recent SLEEMSA study that evaluated excessive daytime sleepiness (EDS) in Caucasian patients
with multiple system atrophy (MSA) demonstrated that EDS was more frequent in patients (28%) than in healthy
subjects (2%). However, the prevalence and determinants of EDS in other ethnic populations have not been
reported to date.
Methods: We performed a single-hospital prospective study on patients with probable MSA. To ascertain the
prevalence and determinants of EDS in Japanese MSA patients, we assessed the patients’ degree of daytime
sleepiness by using the Japanese version of the Epworth Sleepiness Scale (ESS). In addition, we investigated the
effects of sleep-disordered breathing (SDB) and abnormal periodic leg movements in sleep (PLMS), which were
measured by polysomnography, on the patients’ ESS scores.
Results: A total of 25 patients with probable MSA (21 patients with cerebellar MSA and 4 patients with
parkinsonian MSA) were included in this study. All patients underwent standard polysomnography. The mean
ESS score was 6.2 ± 0.9, and EDS was identified in 24% of the patients. SDB and abnormal PLMS were identified in
24 (96%) and 11 (44%) patients, respectively. The prevalences of EDS in patients with SDB and abnormal PLMS were
25% and 18%, respectively. No correlations were observed between ESS scores and the parameters of SDB or
abnormal PLMS.
Conclusions: The frequency of EDS in Japanese patients with MSA was similar to that in Caucasian MSA patients.
SDB and abnormal PLMS were frequently observed in MSA patients, although the severities of these factors were
not correlated with EDS. Further investigations using objective sleep tests need to be performed.
Keywords: Multiple system atrophy, Excessive daytime sleepiness, Epworth Sleepiness Scale, Sleep-disordered
breathing, Abnormal periodic leg movements in sleepBackground
Excessive daytime sleepiness (EDS) is believed to be
caused by disturbed or inadequate sleep [1]. EDS is com-
mon in older adults [2] and is more frequently observed
in patients with underlying sleep disorders, such as sleep
apnea syndrome (SAS), abnormal periodic leg move-
ments in sleep (PLMS), restless legs syndrome (RLS), as
well as neurodegenerative disorders such as Parkinson’s
disease (PD) and Alzheimer’s disease [3].* Correspondence: t-shimo@bri.niigata-u.ac.jp
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distribution, and reproduction in any mediumIn addition, EDS has been considered a common
manifestation of multiple system atrophy (MSA) [3,4].
MSA patients can develop sleep-disordered breathing
(SDB), which is associated with upper-airway obstruction
or central respiratory dysfunction [5-7]. Furthermore,
patients with MSA are known to show impairment of the
neural systems involved in the maintenance of the waking
state, including the cholinergic neurons of the mesopon-
tine tegmentum [8], serotonergic neurons of the rostral
raphe [9], hypocretin/orexin neurons of the lateral hypo-
thalamus [10], and putative wake-active dopaminergic
neurons in the ventral periaqueductal gray matter [11].
These clinical and pathological findings suggest antral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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MSA patients. In fact, the recent SLEEMSA study that
evaluated 86 Caucasian MSA patients (73 parkinsonism
and 13 cerebellar) demonstrated that EDS was present
in 28% of patients with MSA, which was more fre-
quent than that in healthy subjects (2%) [12]. This
study also demonstrated that the symptoms of SDB,
which were indicated by the presence of snoring or
difficulties in breathing during sleep, predicted EDS in
MSA patients. However, as far as we know, there have
been no studies that have investigated the prevalence
of EDS in other ethnic populations and the effects of
SDB or abnormal PLMS [13], as measured by poly-
somnography (PSG), on EDS in MSA patients.
In the present study, we aimed to ascertain the
prevalence of EDS in Japanese MSA patients by using
the Epworth Sleepiness Scale (ESS) [14]. In addition, we
investigated the effects of SDB and abnormal PLMS,
which were measured by PSG, on the ESS scores.Methods
Subjects
This study was approved by the Ethics Committee of
the Niigata University School of Medicine. We per-
formed a single-hospital prospective study on patients
with probable MSA [15] who were admitted to our hos-
pital between 2005 and 2011. Written informed consent
was obtained from all participants. A patient’s degree
of daytime sleepiness was assessed using the Japanese
version of the ESS [16]. Possible scores ranged from 0
for the lowest degree of sleepiness and 24 for the highest
degree of sleepiness. EDS was defined when the ESS
score was greater than 10 [17]. Patients who had not
experienced the situations included in the questionnaire
because of disease progression were asked to estimate
their answers. Assessments were also performed with
the Unified Multiple System Atrophy Rating Scale
(UMSARS) [18] and cognitive function tests, including
the Mini-Mental State Examination (MMSE) [19] and
Frontal Assessment Battery (FAB) [20]. All patients
underwent standard PSG.Data acquisition
Standard PSG was performed with the following mon-
tages: electroencephalography (C3-A2, C4-A1, O1-A2,
and O2-A1); electrooculography; submental electro-
myography; a nasal cannula to measure nasal pressure
and a thermistor to monitor nasal and oral flow; anterior
tibialis movement sensors; inductive plethysmography
for thoracoabdominal motion; electrocardiography; and
arterial oxygen saturation. Esophageal pressure was also
measured in order to monitor the respiratory effort.
Signals were continuously recorded on a 24-channelpolygraph (SomnoStarPro; VIASYS, Yorba Linda, CA,
USA), and the PSG records were evaluated by clinical
technologists who were certified by the Japanese Society
of Sleep Research and blinded to the patients’ clinical
status. The scoring of sleep stages, arousals, and respira-
tory events was done manually from the PSG records
according to the 1999 recommendations of the American
Academy of Sleep Medicine Task Force [21]. SDB was
defined as an apnea-hypopnea index (AHI) of 5 or more
apnea or hypopnea episodes/h, and severe SDB was
defined as an AHI of 30 or more apnea or hypopnea
episodes/h. The periodic leg movement (PLM) index
was calculated on the basis of the number of PLMs/h
in sleep. A PLM index greater than 15 was defined as
an abnormal PLMS according to Version 2 of the Inter-
national Classification of Sleep Disorders. The PLM
arousal index was defined as the number of PLM-related
electroencephalographic arousals/h of sleep. RLS was
diagnosed when patients met the 4 minimal criteria of
the syndrome as defined by an international study group
[22]. In the event of an inability to fall asleep, subjects
were administered a nonbenzodiazepine sedative/hypnotic
(zolpidem, 5 mg) at the beginning of polysomnography.
The calculation of the L-3,4-dihydroxyphenylalanine
(L-dopa)-equivalent dose (LED) was based on its the-
oretical equivalence to L-dopa, as described in previ-
ous reports [23-25] as follows: 100 mg L-dopa with
dopa-decarboxylase inhibitor = 1 mg pergolide = 1.5 mg
of cabergoline = 1 mg of pramipexole. Fiberoptic laryn-
goscopy was performed during wakefulness as well as
under sedation by intravenously injecting propofol [6].Statistical analyses
Relationships between the ESS scores and variables
related to clinical and sleep characteristics were analyzed
by a Spearman’s rank correlation test. Unpaired Student’s
t-tests were used to compare the quantitative variables,
and a Mann–Whitney rank sum test was used when ap-
propriate. Statistical analyses were performed using Sig-
maPlot version 11.0 with the level of significance set
at P < 0.05. The data are presented as mean ± standard
error of mean.Results
Clinical characteristics
We recruited 25 consecutive patients with probable
MSA (Table 1). Of the 25 MSA patients, 21 (84%) had
MSA-cerebellar (MSA-C), and the remaining 4 (16%)
had MSA-parkinsonism (MSA-P). This subtype fre-
quency is consistent with the results obtained by a recent
national epidemiological study in Japan, which showed
that 83% of MSA patients (n = 3,341) have MSA-C,
Table 1 Clinical and sleep characteristics of multiple




Age at onset (years) 62.3 ± 1.7 (46–78)
Disease duration (months) 45.9 ± 4.7 (12–96)
UMSARS 48.0 ± 4.0 (17–82)
ESS 6.2 ± 0.9 (0–15)
Total sleep time (min) 322 ± 18 (103–575)
Sleep efficiency (%) 61.9 ± 2.7 (35–95)
Stage N1 (%) 32.1 ± 2.26 (12.6–57.3)
Stage N2 (%) 46.3 ± 3.1 (11.4–69.8)
Stage N3 (%) 5.2 ± 1.4 (0–21.7)
Stage REM (%) 15.6 ± 2.5 (0–44.9)
Arousal index (/h) 43.0 ± 4.1 (0–79.9)
AI (/h) 19.7 ± 4.7 (0–80.8)
AHI (/h) 41.9 ± 6.4 (4.1–117.3)
Mean SpO2 (%) 93.1 ± 3.2 (82–97)
PLM index (/h) 44.2 ± 11.7 (0–166.0)
PLM arousal index (/h) 2.3 ± 0.9 (0–16.2)
LED (mg/day) 352 ± 50 (25–683)
Values are means ± standard error of the means (SEM; range). MSA, multiple
system atrophy; UMSARS, unified multiple system atrophy rating scale; ESS,
Epworth sleepiness scale; REM, rapid eye movement; AI, apnea index; AHI,
apnea-hypopnea index; SpO2, oxygen saturation; PLM, periodic leg movement;
LED, L-dopa-equivalent dose.
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Japanese patients than in western patients [26].
Four patients were able to walk without help, 20 were
able to walk with the help of a walker, and 1 could
not walk. All 25 patients showed autonomic failure: 15
patients had orthostatic hypotension [15], and 22 had
urinary incontinence. Laryngeal stridor was present in 8
patients (32%). MMSE and FAB scores were 26.4 ± 0.6
(range, 17–30) and 13.7 ± 0.6 (range, 8–18), respectively.
Eleven patients were treated with antiparkinsonian
drugs: L-dopa without dopamine agonists (DAs) was
administered to 8 patients, L-dopa and DAs (cabergoline
or pergolide) were administered to 2 patients. One pa-
tient was administered pramipexole without L-dopa.
The LED of the 11 patients was 345 ± 47 mg/day (range,
25–608 mg/day). Taltirelin hydrate (10 mg/day), which
is a thyrotropin-releasing hormone analog used in
Japan for the treatment of spinocerebellar degener-
ation, was administered to 10 patients. Antidepressants
were administered to 4 patients. Clonazepam and anti-
psychotic drugs were not routinely administered to any
of the patients. Ten patients received zolpidem (5 mg) at
the beginning of their study because of difficulty in
sleeping.Sleep characteristics
In MSA patients, the ESS score was 6.2 ± 0.9 (range,
0–15), and the prevalence of EDS was 24% (6/25)
(Table 1). No MSA patients reported a sudden onset of
sleep. PSG findings showed that the sleep efficiency of
MSA patients was reduced (61.9 ± 2.7%). The sleep pat-
tern of MSA patients was characterized by reductions
in non-rapid eye movement (REM) stage 3 (N3; 5.2 ±
1.4%; normal value, 13–23%) and mild reductions in
the REM stage (15.6 ± 2.5%; normal value, 20–25%) in
comparison to the previously published normal values
[27]. The AHI was 41.9 ± 6.4 (4.1–117.3) events per hour,
and the central, mixed, and obstructive AHIs were 3.0 ±
1.6 (0–40.7), 2.5 ± 1.2 (0–23.3), and 36.4 ± 5.3 (3.4–82.5)
events per hour, respectively. A total of 24 MSA patients
(96%) fulfilled the SDB criteria, and the prevalence of
EDS in MSA patients with SDB was 25% (6 out of the
24 patients). All patients had predominantly obstructive
SDB, although 19 patients also had central SDH. The
frequencies of vocal cord abductor paralysis, floppy
epiglottis [28], and oropharyngeal obstruction were 15/25
(60%), 9/25 (36%), and 8/25 (32%), respectively. Eight
patients developed upper airway obstructions at more
than one site. Fourteen patients (56%) met the criteria
for severe SDB, and the prevalence of EDS in the patients
with severe SDB was 21% (3 out of the 14 patients).
Abnormal PLMS was observed in 44% (11 of the
25 patients) of the patients, and the prevalence of EDS
in the patients with abnormal PLMS was 18% (2 of the
11 patients). RLS was observed in 12% (3 out of the
25 patients) of the patients, and none of the patients
with RLS showed EDS.
Effects of clinical and sleep characteristics on ESS scores
No correlations were observed between the ESS scores
and disease duration, disease severity as assessed by
UMSARS scores, or cognitive function as assessed by
MMSE and FAB scores (Table 2). The PSG findings indi-
cated no correlations between ESS scores and the para-
meters of SDB [apnea index (AI), AHI, and mean oxygen
saturation (SpO2) levels] and abnormal PLMS (PLM
index and PLM arousal index). In the 11 patients treated
with antiparkinson drugs, a significant positive correl-
ation was found between ESS scores and LED (r = 0.662,
P = 0.027).
Discussion
The present study showed that the ESS score in our
MSA patients was 6.2 ± 0.9. This ESS score was higher
than the previously published score in Japanese healthy
subjects (4.1 ± 0.3; n = 79; mean age, 67.0 ± 1.2) [29].
The prevalence of EDS in our MSA patients was 24%.
This prevalence was similar to that reported in the
SLEEMSA study [12], which demonstrated that the
Table 2 Correlations between the Epworth sleepiness
scale (ESS) scores and clinical and sleep characteristics of
multiple system atrophy (MSA) patients
Variables r value P value




Total sleep time (min) 0.262 0.215
Sleep efficiency (%) 0.297 0.149
Stage N1 (%) 0.138 0.512
Stage N2 (%) 0.179 0.391
Stage N3 (%) −0.267 0.197
Stage REM (%) −0.311 0.131
Arousal index (/h) −0.070 0.738
AI (/h) 0.069 0.744
AHI (/h) 0.098 0.640
Mean SpO2 (%) 0.080 0.705
PLM index (/h) −0.218 0.296
PLM arousal index (/h) 0.066 0.755
LED (mg) 0.662 0.027
UMSARS, unified multiple system atrophy rating scale; MMSE, mini-mental
state examination; FAB, frontal assessment battery; REM, rapid eye movement;
AI, apnea index; AHI, apnea-hypopnea index; SpO2, oxygen saturation; PLM,
periodic leg movement; LED, L-dopa-equivalent dose.
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able to that in PD patients (29%), but the prevalence was
higher than that in healthy subjects (2%). These findings
raise the possibility that EDS is a common clinical fea-
ture in MSA patients despite the differences in ethnicity
as well as in subtype [26,30].
We also analyzed the effects of SDB and abnormal
PLMS on EDS. Consistent with the results of previous
studies [6,13], SDB was frequently observed in our study.
A total of 24 patients (96%) met the criteria for SDB,
and 56% of the patients met the criteria for severe SDB.
The recent SLEEMSA study demonstrated the correl-
ation between SDB, which was based on questionnaires,
and EDS [12]. However, this study showed that there
was no correlation between ESS scores and the para-
meters of SDB, which are AI, AHI, and mean SpO2
levels, in MSA patients, whereas SDB scores correlated
with the EDS in patients with obstructive SAS in other
studies [14,31]. These results suggest that SDB may not
necessarily have a strong influence on EDS in MSA
patients.
Although abnormal PLMS may be observed in MSA
patients, there is no evidence that an increased preva-
lence of abnormal PLMS causes sleep disturbances and
EDS in MSA patients. Vetrugno et al. reported that 15
of 18 patients with MSA (88%) presented with abnormal
PLMS [13]. In the present study, the prevalence ofabnormal PLMS was 44%, indicating that abnormal
PLMS was frequently associated with MSA despite the
differences in ethnicity, although it was less frequent
than in the previous study [13]. We speculate that ab-
normal PLMS may not have a strong influence on EDS
in MSA patients, because we did not find any significant
correlations between the ESS scores and the indexes for
PLM and PLM arousal. A lack of correlation between
EDS and AHI or PLMS suggested an impairment of the
normal sympathetic response to sleep apnea in MSA.
We showed that the disease duration and severity,
impairments of cognitive or frontal function, as well as
sleep quality that was evaluated by PSG, were not asso-
ciated with EDS, while we identified a dose-dependent
effect of antiparkinson drugs on EDS. Although this
finding was not consistent with the SLEEMSA study,
which showed a lack of correlation between the amount
of dopaminergic treatment and EDS [12], it suggests still
another possibility that antiparkinson drugs may cause
EDS, as is the case with PD [32]. However, because 84%
of the patients in the present study had MSA-C, we were
able to recruit only 11 patients who had been treated
with antiparkinson drugs. In addition, it remains the
possibility that there may be confounding factors that
are correlated with EDS and LED, such as the disease
severity and duration. Further studies should be per-
formed in order to further investigate the effects of
antiparkinson drugs on sleepiness in MSA patients.
As mentioned above, the major determinant of EDS in
MSA patients remains unknown. It is possible that the
involvement of the arousal system may be a determinant
of EDS in patients with MSA. In addition, as has been
reported for patients with Parkinson’s disease, several
factors, such as depressive symptoms, hallucinations,
psychosis, nocturia, and nocturnal motor symptoms, can
be possible causes of the EDS in MSA patients [32].
This study had several limitations. The first limitation
of this study was that some of the subjects were adminis-
tered a DA (3 patients) or an antidepressant (4 patients),
and these medications can cause daytime sleepiness. The
second limitation was the uncertainty over whether ESS
is a suitable method for evaluating daytime sleepiness
in MSA patients. This uncertainty may stem from the
difficulty in ascertaining that MSA patients accurately
rated their likelihood of falling asleep in some situations
that they did not experience after disease progression.
These limitations suggest the need for further investiga-
tions to determine objective sleep tests, such as a mul-
tiple sleep latency test, in MSA patients.
Conclusions
The frequency of EDS in Japanese MSA patients (24%)
was similar to that in Caucasian MSA patients (28%) in
spite of the difference in the frequency of subtypes. SDB
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patients (96% and 64%, respectively), although the sever-
ities of these factors were not correlated with EDS.
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